Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Gastrointestinal 4Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 56Lung Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 5Neoplasms 5Neoplasm Metastasis 4Colorectal Neoplasms 4Colonic Neoplasms 3Advanced Solid Tumors 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Pancreatic Neoplasms 2Non-squamous Non-small Cell Lung Cancer 2Mesothelioma 2Meningeal Carcinomatosis 2Melanoma 2Lung Diseases 2Esophageal Neoplasms 2Carcinoma 2Adenocarcinoma of Lung 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pathologic Processes 1Pathologic Complete Response 1Ovarian Neoplasms 1

Interventions

Bevacizumab 28Fluorouracil 24Oxaliplatin 22Specimen Handling 21Leucovorin 21Cetuximab 19pembrolizumab 14Biopsy 14Magnetic Resonance Spectroscopy 12Irinotecan 12Folfox protocol 8Nivolumab 7Capecitabine 7balstilimab 6Panitumumab 6IFL protocol 6HMPL-013 5trifluridine tipiracil drug combination 4fludarabine 4dehydroftorafur 4atezolizumab 4X-Rays 4Standard of Care 4Pemetrexed 4Immunoglobulin G 4Disulfides 4Cyclophosphamide 4Cisplatin 4Carboplatin 4encorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Pemetrexed × 30 days × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06704724 2026-05-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Pfizer

Phase 1 Terminated
30 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT07397338 2026-05-12

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Revolution Medicines, Inc.

Phase 1/2 Recruiting
370 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT04083599 2026-05-06

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Genmab

Phase 1/2 Active not recruiting
350 enrolled
DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡